In this episode, Andrew Huberman discuss what psilocybin is (chemically) and how it works at the cellular and neural circuit level to trigger neuroplasticity, which is our brain’s ability to rewire itself in ways that lead to long-lasting shifts in our emotional, cognitive and behavioral patterns and abilities. He discusses the emerging clinical trial evidence for the use of psilocybin in the treatment of depression, addictions and other psychiatric challenges. He also explains the typical duration and phases of a psilocybin journey, the different categories of dosages often used and explains the importance of set, setting and support when using psychedelics. He explains which groups of people place themselves at great risk by taking psilocybin as well as groups that could benefit, and highlights the rapidly changing legal and medical landscape around psilocybin. This episode is a thorough exploration of psilocybin from the scientific and clinical literature perspective and ought to be of interest to anyone curious about psilocybin, mental health, neuroplasticity and/or psychedelics more generally.
